Shares of Hims & Hers Health Around 26% closed on Friday after the US Food and Drug Administration announced that the lack of Semaglutide injection products was solved.
Semaglutid is the active ingredient in Novo Nordisks Blockbuster -Weight loss -Ticament Wegovy and Diabetes Treatment Ozempic. These drugs have been part of a class of medication called GLP-1, and the demand for treatments has exploded in recent years. As a result, digital health companies such as HIMS & HER have prescribed SEMAGLUTID as an alternative for patients who navigate volatile care hurdles and insurance obstacles.
Composite drugs are custom -made alternatives to brand medication that should meet the needs of a certain patient, and compouss can produce if brand treatments are lacking. The FDA does not check the safety and effectiveness of compiled products.
Hims & Hers started an increased Semaglutid in May and has compounding pharmacies that produce the medication.
Medicines are usually much cheaper than their brand colleagues. HIMS & HERS sells Semaglutid for less than 200 US dollars per month, while Ozempic and Wegovy both cost around $ 1,000 per month without insurance.
The FDA said on Friday that it would take against connections against connections in the next 60 to 90 days, depending on the type of facility to “avoid unnecessary disorders of the patient treatment”.
“After the FDA has determined that the lack of drugs for Semaglutide has been solved, we will continue to provide access to personalized treatments that are legally permissible in order to meet the needs of patients” also the potential future lack of monitoring future surveillance, such as Novo Nordisk found two weeks ago that there were still “capacity restrictions” and “expected regular restrictions on offer And would have associated notifications about a lack of drugs.
The offer of him and her weight loss was a massive hit among investors. The company's shares rose by more than 200% last year, and the share has already increased more than 100% this year, although the move on Friday on Friday.
Before it has included GLP-1 in its portfolio, the company said in its 2023 earnings in the fourth quarter that it would expect its weight loss program to achieve sales of more than $ 100 million by the end of 2025.
Despite the turbulent regulatory landscape, Hims & here showed no signs of slowing down.
On Friday, the company announced that it has acquired a peptide facility based in the USA, in which “the company's long-term ability to provide personalized medication will continue to verticalize”. HIMS & HER will examine progress in metabolic optimization, relaxation science, biological resistance, cognitive performance and preventive health through the acquisition, the company said.
This step comes only a few days after Hims & Huse also bought Trybe Labs, the laboratory test facility based in New Jersey at home. With trylbe Labs, HIMS & HUSE can carry out blood streets and more comprehensive pretreatment tests.
Hims & Hins did not open the conditions of a two deals.
REGARD: Hims & Hers Super Bowl ad Sparks controversies
Comments are closed.